Liver transplantation in patients with HIV infection;Trasplante hepático en pacientes con infección por VIH

Gastroenterologia y Hepatologia

Volumn 33, Issue 9, 2010, Pages 660-669

  Rafael Valdivia, Lourdes ^a   Miró, José M ^b   Rimola, Antoni ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Hepatitis C virus; Human immunodeficiency virus; Liver transplantation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CAUSE OF DEATH; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TRANSPLANTATION; MIXED INFECTION; PATIENT SELECTION; RECURRENT INFECTION; SURVIVAL;

EID: 78149360589     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2010.01.007     Document Type: Article

References (87)

1. Samuel D., Weber R., Stock P., Duclos-Vallée J.C., Terrault N. Are HIV-infected patients candidates for liver transplantation?. J Hepatol 2008, 48:697-707.
2. Dinh M.H., Stosor V., Rao S.M., Miller F.H., Green R.M. Cryptogenic liver disease in HIV-seropositive men. HIV Med 2009, 10:447-453.
3. Mallet V., Blanchard P., Verkarre V., Vallet-Pichard A., Fontaine H., Lascoux-Combe C., et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007, 21:187-192.
4. González-García J.J., Mahillo B., Hernández S., Pacheco R., Diz S., García P., et al. Estudio multicentrico sobre prevalencia de las coinfecciones por virus de la hepatitis, indicación de tratamiento de hepatitis crónica C y necesidad de trasplante hepático en pacientes infectados por el VIH en España. Estudio GESIDA 29/02-FIPSE 12185/01. Enferm Infecc Microbiol Clin 2005, 23:340-348.
5. Pérez Cachafeiro S., Del Amo J., Iribarren J.A., Salavert Lleti M., Gutiérrez F., Moreno A., et al. Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. Clin Infect Dis 2009, 48:1467-1470.
6. Mohsen A.H., Easterbrook P.J., Taylor C., Portmann B., Kulasegaram R., Murad S., et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003, 52:1035-1040.
7. Thein H.H., Yi Q., Dore G.J., Krahn M.D. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008, 22:1979-1991.
8. Kim A.Y., Chung R.T. Coinfection with HIV-1 and HCV-A one-two punch. Gastroenterology 2009, 137:795-814.
9. Pineda J.A., Romero-Gómez M., Díaz-García F., Girón-González J.A., Montero J.L., Torre-Cisneros J., et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related descompensated cirrhosis. Hepatology 2005, 41:779-789. Grupo Andaluz para el Estudio de las Enfermedades Infecciosas; Grupo Andaluz para el Estudio del Hígado.
10. Murillas J., Rimola A., Laguno M., de Lazzari E., Rascón J., Agüero F., et al. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transplant 2009, 15:1133-1141. ESLD-HIV Working Group Investigators.
11. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., González-García J., Lazzarin A., et al. Peginterferon alfa-2a plus ribavirn for chronic hepatitis C virus infection in HIV infected patients. NEJM 2004, 351:438-450. APRICOT Study Group.
12. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A., et al. Pegylated interferon alfa-2b vs standard alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-2848.
13. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-coinfected persons. NEJM 2004, 351:451-459. AIDS Clinical Trials Group A5071 Study Team.
14. Laguno M., Murillas J., Blanco J.L., Martínez E., Miquel R., Sánchez-Tapias J.M., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa -2b plus ribavirin for treatment of HIV/ HCV co-infected patients. AIDS 2004, 18:F27-F36.
15. Martín-Carbonero L., Benhamou Y., Puoti M., Berenguer J., Mallolas J., Quereda C., et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004, 38:128-133.
16. Schiavini M., Angeli E., Mainini A., Zerbi P., Duca P.G., Gubertini G., et al. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med 2006, 7:331-337.
17. Operskalski E.A., Mack W.J., Strickler H.D., French A.L., Augenbraun M., Tien P.C., et al. Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J Clin Virol 2008, 41:255-263.
18. Sulkowski M.S., Mehta S.H., Chaisson R.E., Thomas D.L., Moore R.D. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004, 18:2277-2284.
19. Labarga P., Soriano V., Vispo M.E., Pinilla J., Martin-Carbonero L., Castellares C., et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007, 196:670-676.
20. Miro J.M., Montejo M., Rufi G., Bárcena R., Vargas V., Rimola A., et al. Trasplante hepático en pacientes con infección por el VIH: una realidad en el año 2004. Enf Infecc Microbiol Clini 2004, 22:529-538.
21. Puoti M., Bruno R., Soriano V., Donato F., Gaeta G.B., Quinzan G.P., et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004, 18:2285-2293. HIV HCC Cooperative Italian-Spanish Group.
22. Bräu N., Fox R.K., Xiao P., Marks K., Naqvi Z., Taylor L.E., et al. Presentation and outcome of hepatocellular carcinoma in HIV- infected patients: a US Canadian multicenter study. J Hepatol 2007, 47:527-537. North American Liver Cancer in HIV Study Group.
23. Tzakis A.G., Cooper M.H., Dummer J.S., Ragni M., Ward J.W., Starzl T.E. Transplantation in HIV+ patients. Transplantation 1990, 49:354-358.
24. Erice A., Rhame F.S., Heussner R.C., Dunn D.L., Balfour H.H. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis 1991, 13:537-547.
25. Bouscarat F., Samuel D., Simon F., Debat P., Bismuth H., Saimot A.G. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin Infect Dis 1994, 19:854-859.
26. Gordon F.H., Mistry P.K., Sabin C.A., Lee C.A. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998, 42:744-749.
27. Lewden C., Salmon D., Morlat P., Bévilacqua S., Jougla E., Bonnet F., et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005, 34:121-130. Mortality 2000 study group.
28. Salmon-Ceron D., Lewden C., Morlat P., Bévilacqua S., Jougla E., Bonnet F., et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005, 42:799-805. Mortality 2000 study group.
29. Martínez E., Milinkovic A., Buira E., de Lazzari E., León A., Larrousse M., et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med 2007, 8:251-258.
30. Neff G.W., Bonham A., Tzakis A.G., Ragni M., Jayaweera D., Schiff E.R., et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003, 9:239-247.
31. Ragni M.V., Belle S.H., Im K., Neff G., Roland M., Stock P., et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003, 188:1412-1420.
32. Fung J., Eghtesad B., Patel-Tom K., DeVera M., Chapman H., Ragni M. Liver transplantation in patients with HIV infection. Liver Transplant 2004, 10(Suppl 2):S39-S53.
33. Norris S., Taylor C., Muiesan P., Portmann B.C., Knisely A.S., Bowles A., et al. Outcomes of liver transplantation in HIV-infected individuals: The impact of HCV and HBV infection. Liver Transplant 2004, 10:1271-1278.
34. De Vera M.E., Dvorchik I., Tom K., Eghtesad B., Thai N., Shakil O., et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006, 6:2983-2993.
35. Schreibman I., Gaynor J.J., Jayaweera D., Pyrsopoulos N., Weppler D., Tzakis A., et al. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 2007, 84:697-705.
36. Roland M.E., Barin B., Carlson L., Frassetto L.A., Terrault N.A., Hirose R., et al. HIV-infected liver and kidney transplant recipients: 1-and 3- year outcomes. Am J Transplant 2008, 8:355-365.
37. Duclos-Vallée J.C., Féray C., Sebagh M., Teicher E., Roque-Afonso A.M., Roche B., et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008, 47:407-417. THEVIC Study Group.
38. Mindikoglu A.L., Regev A., Magder L.S. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation 2008, 85:359-368.
39. Baccarani U., Adani G.L., Tavio M., Lorenzin D, Londero A, Braganti F, et al. Liver transplantation in HIV positive patients: Comparison with a matched HIV negative population. Am J Transplant 2009, 9(suppl. 2):260. [abstr].
40. Joshi D., Aluvihare V., Belgaumkar A., O'Grady J., Suddle A, Heneghan V, et al. Liver transplantation for HIV: Long term outcomes from the UK. Am J Transplant 2009, 9(suppl. 2):S74. [abstr].
41. Rimola A., Montejo M., Castells L., Meneu J.C., Rafecas A., Blanes M., et al. Supervivencia postrasplante hepático en pacientes con coinfección VIH-VHC. Resultados preliminares de un estudio multicéntrico español de casos y controles. Gastroenterol Hepatol 2009, 32:107. [abstract].
42. Miró J.M., Torre-Cisnero J., Moreno A., Tuset M., Quereda C., Laguno M., et al. GESIDA/ GESITRA- SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005). Enferm Infecc Microbiol Clin 2005, 23:353-362.
43. Roland M.E., Stock P.G. Solid organ transplantation is a reality for patients with HIV infection. Curr HIV/AIDS Rep 2006, 3:132-138.
44. Prieto M., Clemente G., Casafont F., Cuende N., Cuervas-Mons V., Figueras J., et al. Documento de consenso de indicaciones de trasplante hepático. Gastroenterol Hepatol 2003, 26:355-375.
45. Documento de consenso de la Sociedad Española de Trasplante Hepático. Acceso al trasplante hepático, indicaciones controvertidas, priorización de la lista de espera e indicadores de calidad. Gastroenterol Hepatol 2008, 31:82-91. Sociedad Española de Trasplante Hepático.
46. Documento de consenso de la Sociedad Española de Trasplante Hepático. Lista de espera, trasplante pediátrico e indicadores de calidad. Gastroenterol Hepatol 2009, 32:702-716. Sociedad Española de Trasplante Hepático.
47. Lligoña A., Freixa N., Bataller R., Monras M., Rimola A. Guia Clínica de evaluación de pacientes con conductas adictivas para trasplante hepatico. Gastroenterol Hepatol 2009, 32:155-161.
48. Terrault N.A., Carter J.T., Carlson L., Roland M.E., Stock P.G. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transplant 2006, 12:801-807.
49. Vennarecci G., Ettorre G.M., Antonini M., Santoro R., Perracchio L., Visco G., et al. Liver transplantation in HIV-positive patients. Transplant Proc 2007, 39:1936-1938.
50. Maida I., Núñez M., González-Lahoz J., Soriano V. Liver transplantation in HIV-HCV coinfected candidates: what is the most appropriate time for evaluation?. AIDS Res Hum Retroviruses 2005, 21:599-601.
51. Di Benedetto F., De Ruvo N., Berretta M., Masetti M, Montalti R, Di Sandro S, et al. Hepatocellular carcinoma in HIV patients treated by liver transplantation. Eur J Surg Oncol 2008, 34:422-427.
52. Vargas V., Rimola A., Casanovas T., Castells L., Navasa M., Baliellas C., et al. Applicability of liver transplantation in Catalonia at the end of the millennium. A prospective study of adult patient selection for liver transplantation. Transpl Int 2003, 16:270-275.
53. Ragni M.V., Eghtesad B., Schlesinger K.W., Dvorchick I., Fung J. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end stage liver disease. Liver Transplant 2005, 11:1425-1430.
54. Prieto J.E., Laguno M., Aguero F., Freixa N., Monras M., Cervera C., et al. Evaluation of cirrhotic patients with HIV infection (HIV+) as candidates for liver transplantation. Liver Transplant 2008, 14(suppl 1):S223. [abstract].
55. Carmona D., Delvart V., Antonini T.M., Sobesky R., Roche B., Teicher E., et al. Analyse of predictive factors of mortality of HIV/HCV infected patients in the waiting list of liver transplantation. Liver Transplant 2009, 15(suppl 1):S157. [abstract].
56. Pache I., Duclos-Vallee J.-C., Teicher E., Bismuth H., Castaign D., Vittecoq D., et al. Indications and timing for liver transplantation in HIV co-infected patients. Hepatology 2004, 40:356A. [abstract].
57. Merchante N., Giron-Gonzales J.A., González-Serrano, Torre Cisneros J, Garcia-Garcia JA, Arizcorreta A, et al. Survival and prognostic factors of HIV - infected patients with HCV-related end-stage liver disease. AIDS 2006, 20:49-57.
58. Castells L., Esteban J.I., Bilbao I., Vargas V., Allende H., Ribera E., et al. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV- infected patients. Antivir Ther 2006, 11:1061-1070.
59. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008, 49:274-287.
60. Samuel D., Bizollon T., Feray C., Roche B., Ahmed S.N., Lemonnier C., et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003, 124:642-650.
61. Fredrick T.R., Hassanein T.I. Rol of growth factors in the treatment of patients with HIV/ HCV coinfection and patients with recurrent hepatitis C following liver transplantation. J Clin Gastroenterol 2005, 39(suppl. 1):S14-S22.
62. Wojcik K., Vogel M., Voigt E., Speidel N., Kalff J.C., Goldmann G., et al. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. AIDS 2007, 21:1363-1365.
63. Watt K., Veldt B., Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 2009, 9:1707-1713.
64. Firpi R.J., Zhu H., Morelli G., Abdemalek M.F., Soldevila-Pico C., Machicao V.I., et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transplant 2006, 2:51-57.
65. Duclos-Vallée J.C., Roche B., Samuel D. Transplantation hépatique chez les patients porteurs des virus de l'hépatite B, de l'hépatite C et du virus de l'immunodéficience humaine. Presse Med 2009, 38:1281-1289.
66. Tateo M., Roque-Afonso A.-M., Antonini T.M., Medja F., Lombes A., Jardel C., et al. Long-term follow up of liver transplanted HIV/ hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009, 23:1069-1076.
67. Coffin C.S., Berg C.L., Dove L.M., Poordad F., Curry M., Regenstein F.G., et al. Survival and risk of Hepatitis B virus (HBV) recurrente in HIV-HBV coinfected liver transplant recipients: Preliminary findings form the HIV-TR study. Hepatology 2007, 46:245A. [abstract].
68. Papatheodoridis G.V., Cholongitas E., Archimandritis A.J., Burroughs A.K. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009, 29:1294-1305.
69. Rafecas A., Rufí G., Figueras J., Fabregat J., Xiol X., Ramos E., et al. Liver transplantation without steroid induction in HIV-infected patients. Liver Transplant 2004, 10:1320-1323.
70. Polak W.G., Gladysz A. Solid organ transplantation and HIV infection. Ann Transplant 2003, 8:16-21.
71. Chapuis A.G., Paolo Rizzardi G., D'Agostino C., Attinger A., Knabenhans C., Fleury S., et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000, 6:762-768.
72. Izzedine H., Launay-Vacher V., Baumelou A., Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 2004, 66:532-541.
73. Heredia A., Latinovic O., Gallo R.C., Melikyan G., Reitz M., Le N., Redfield R.R. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci 2008, 105:20476-20481.
74. Marfo K., Greenstein S. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplant Proc 2009, 41:3796-3799.
75. Clarke A., Stein A.R., Townsend M.L. Drug-Drug interactions with HIV antiretroviral therapy. US Pharm 2008, 33:HS3-HS21.
76. Frassetto L.A., Browne M., Cheng A., Wolfe A.R., Roland M.E., Stock P.G., Carlson L., et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007, 7:2816-2820.
77. Teicher E., Laurence I., Bonhomme-Faivre L., Abbara C., Barrail A., Boissonnas A., et al. Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study. Clin Pharmacokinet 2007, 46:941-953.
78. Tricot L., Teicher E., Peytavin G., Zucman D., Conti F., Calmus Y., et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009, 9:1946-1952.
79. Duclos-Vallée J.C., Vittecoq D., Teicher E., Feray C., Roque-Afonso A.M., Lombès A., et al. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. J Hepatol 2005, 42:341-349.
80. Antoniades C., Macdonald C., Knisely A., Taylor C., Norris S. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipients. Liver Transplant 2004, 10:699-702.
81. Galpérine T., Merle C., De Truchis P., Bernard L., Peroné C. Tolérance et interactions médicamenteuses des traitements anti-VIH et anti-VHC. Med Malad Infect 2005, 35:135-140.
82. Peronne C. Antiviral hepatitis and antiretroviral drug interactions. J Hepatol 2006, 44:119-125.
83. Fleischer R., Boxwell D., Sherman K. Nucleosid analogues and mitocondrial toxicity. Clin Infect Dis 2004, 38:e79-e80.
84. Soriano V., Miro J.M., García Samaniego J., Torre-Cisneros J., Nuñez M., Del Romero J., et al. Consensus conference on chronic viral hepatitis and HIV infection: Update Spanish recommendations. J Viral Hepat 2004, 11:2-17.
85. Dasgupta A., Okhuysen P. Pharmacokinetics and other drug interactions in patients with AIDS. Ther Drug Monit 2001, 23:591-605.
86. DHHS panel on antiretroviral Guidelines for Adults and Adolescents - A working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Dirección electrónica: Acceso electrónico: 9-12-2009. http://www.aidsinfo.inh.gov/ContentFiles/AdultandAdolescentGL.pdf.
87. Recomendaciones de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización febrero de 2009). Enferm Infecc Microbiol Clin 2009, 27:222-235. Panel de expertos de Gesida y Plan Nacional sobre el Sida.